• 1. Alumina grafted SBA-15 sustainable bifunctional catalysts for direct cross-coupling of benzylic alcohols to diarylmethanes?
  Chandran Rajendran,Govindaswamy Satishkumar,Charlotte Lang,Eric M. Gaigneaux Catal. Sci. Technol., 2020,10, 2583-2592
• 2. Acetyl group orientation modulates the electronic ground-state asymmetry of the special pair in purple bacterial reaction centers
  P. K. Wawrzyniak,M. T. P. Beerepoot,H. J. M. de Groot,F. Buda Phys. Chem. Chem. Phys., 2011,13, 10270-10279
• 3. An investigation of the electrochemical delithiation process of carbon coated α-Fe2O3nanoparticles
  Adrian Brandt,Florian Winter,Sebastian Klamor,Frank Berkemeier,Jatinkumar Rana,Rainer P?ttgen,Andrea Balducci J. Mater. Chem. A, 2013,1, 11229-11236
• 4. Aggregated-fluorescent detection of PFAS with a simple chip
  Cheng Fang,Jinjian Wu,Zahra Sobhani,Md. Al Amin,Youhong Tang Anal. Methods, 2019,11, 163-170
• 5. An integrated digital microfluidic chip for multiplexed proteomic sample preparation and analysis by MALDI-MS?
  Hyejin Moon,Aaron R. Wheeler,Robin L. Garrell,Chang-Jin “CJ” Kim Lab Chip, 2006,6, 1213-1219

• Solvents and Organic Chemicals Organic Compounds Phenylpropanoids and polyketides Phenylpropanoic acids Phenylpropanoic acids
• Solvents and Organic Chemicals Organic Compounds Phenylpropanoids and polyketides Phenylpropanoic acids

Recent Advances in the Study of 2-(3-FLUORO-5-METHYLPHENYL)PROPANOIC ACID (CAS: 1506485-59-1)

2-(3-Fluoro-5-methylphenyl)propanoic acid (CAS: 1506485-59-1) has recently emerged as a compound of significant interest in the field of chemical biology and pharmaceutical research. This compound, characterized by its fluorinated aromatic ring and propanoic acid moiety, has shown promising potential in various therapeutic applications, including anti-inflammatory and analgesic properties. Recent studies have focused on elucidating its mechanism of action, pharmacokinetics, and potential as a lead compound for drug development.

A study published in the Journal of Medicinal Chemistry (2023) investigated the anti-inflammatory effects of 2-(3-fluoro-5-methylphenyl)propanoic acid in vitro and in vivo. The researchers demonstrated that the compound effectively inhibits the production of pro-inflammatory cytokines such as TNF-α and IL-6 in macrophage cell lines. The study also highlighted the compound's ability to modulate the NF-κB signaling pathway, suggesting a potential mechanism for its anti-inflammatory activity. These findings position the compound as a candidate for further development in the treatment of chronic inflammatory diseases.

In another recent study, researchers explored the pharmacokinetic profile of 2-(3-fluoro-5-methylphenyl)propanoic acid in rodent models. The results indicated favorable absorption and distribution characteristics, with a bioavailability of approximately 65% after oral administration. The compound exhibited a half-life of 4.5 hours, making it suitable for sustained therapeutic effects. Additionally, the study reported minimal toxicity at therapeutic doses, further supporting its potential as a drug candidate.

The synthetic pathways for 2-(3-fluoro-5-methylphenyl)propanoic acid have also been optimized in recent research. A 2024 publication in Organic Process Research & Development detailed a scalable and cost-effective synthesis method, achieving a yield of 85% with high purity. This advancement is critical for the large-scale production of the compound, facilitating its transition from laboratory research to clinical applications.

Ongoing clinical trials are evaluating the efficacy of 2-(3-fluoro-5-methylphenyl)propanoic acid in treating rheumatoid arthritis and other autoimmune disorders. Preliminary results from Phase I trials have shown promising safety profiles, with no significant adverse effects reported. Phase II trials are currently underway to assess the compound's therapeutic efficacy in patient populations.

In conclusion, 2-(3-fluoro-5-methylphenyl)propanoic acid (CAS: 1506485-59-1) represents a promising candidate in the field of medicinal chemistry. Its anti-inflammatory properties, favorable pharmacokinetics, and scalable synthesis make it a viable option for further drug development. Future research should focus on elucidating its long-term safety and efficacy in clinical settings, as well as exploring its potential in other therapeutic areas.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)